| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. | Ann Oncol | 2008 | 0.97 |
| 2 | Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. | Clin Pharmacol Ther | 2007 | 0.83 |
| 3 | Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. | Cancer Chemother Pharmacol | 2011 | 0.81 |